An observational study in Cerebral Amyloid Angiopathy, Small Vessel Cerebrovascular Disease and Cadasil, sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 1 site in Switzerland. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2023-03-08.
Sponsored by Insel Gruppe AG, University Hospital Bern · Observational
Prognosis of small vessel disease (SVD) depends on the underlying type of SVD and index manifestation.
The aim of this prospective, observational cohort study is to determine the risk of different outcome events among patients with SVD according to the type of index presentation.
37 studies on the registry are indexed under Cerebral Amyloid Angiopathy; 8 are open to participants now.
This study's planned enrollment of 900 is above the median of 81 across 18 observational studies indexed under Cerebral Amyloid Angiopathy.
Browse Cerebral Amyloid Angiopathy studies →Insel Gruppe AG, University Hospital Bern is the lead sponsor of 741 studies on the registry; 180 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This is a prospectively recruited cohort of patients treated with cerebral small vessel disease at Inselspital Bern University Hospital. Patients are recruited at the emergency department, neurology in-patient ward, Stroke Unit, IMC, ICU and outpatient clinics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intracerebral haemorrhage (ICH)
Non-traumatic, intracerebral haemorrhage (ICH, including convexity subarachnoid haemorrhage)
Time frame: 1 year
Ischaemic stroke
Defined by CT and/or MRI
Time frame: 1 year
Cardio-vascular death
According to the treating physician
Time frame: 1 year
Other intracranial bleeding
Subdural haematoma, subarachnoid haemorrhage
Time frame: 1 year
Other (transient) neurological attacks
Including transient ischaemic attack (TIA), transient neurological attack (TNA), amyloid spells, (focal) seizures
Time frame: 1 year
Cognitive impairment
Montreal Cognitive Assessment (MoCA, range 0-30 points) \< 26 points (corresponding to impaired cognitive function) and/or new impairment in activities of daily living as defined by the treating physician.
Time frame: 1 year
New-onset of extracranial vascular disease
As judged by the treating physician
Time frame: 1 year
Functional outcome
Modified Rankin scale score (ordinal score, range 0-6, a score of 0 corresponds to no symptoms at all, while a score of 6 corresponds to death)
Time frame: 1 year
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Insel Gruppe AG, University Hospital Bern →